Semax Dosage and Nasal Protocol: A Clinical Guide for Standard, NA-Semax, and the Amidate Form

The single most common question after someone decides to trial Semax is not about its mechanism or its clinical history — it is about the bottle in their hand. How many drops? Which nostril first? Is the NA-Semax dose the same? What changes if they are cycling it for neuroprotection versus acute cognitive load?

This article answers those questions with the precision they deserve, and it is just as precise about where the evidence stops. I have covered the mechanistic background for Semax elsewhere; here the focus is on administration — variant-by-variant dosing, titration sequences, cycling frameworks, and the practical technique details that determine whether the peptide actually gets absorbed — alongside what the human data do and do not show.

At a Glance

Anti-doping (WADA 2026): Semax is not named on the list, but section S0 covers any pharmacological substance without current human-use approval by a governmental health authority. Athletes should check with their national anti-doping organisation.

Protocol Table: Dose, Route, Timing and Basis

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

One row per use case. Basis: Label (registered product information), Trial (published human study, PMID), Practice protocol (reported by at least two independent compilations), Anecdotal (community reports only). The Russian label states that one drop of the 0.1% solution contains 50 mcg and one drop of the 1% solution 500 mcg.

The label doses run higher than most community doses: a single registered dose of the 0.1% product starts at 200 mcg, and the stroke regimens use the 1% product at 6,000-20,000 mcg a day. Community users mostly stay at 200-900 mcg a day, and their reports of overstimulation and headache cluster above that range.

What Semax Is and What It Does

Semax is a short synthetic peptide derived from the 4-7 segment of adrenocorticotropic hormone (ACTH), with a Pro-Gly-Pro tail added to slow its breakdown. Unlike ACTH it does not stimulate cortisol release in a meaningful way. It was developed in Russia and is used there as an intranasal drug, mainly in acute and recovering stroke.

The mechanism data come almost entirely from rodents:

• BDNF signalling. In rats, Semax raised hippocampal levels of brain-derived neurotrophic factor (BDNF) and its receptor trkB [1]. BDNF supports synaptic plasticity, which is why Semax is used as a “nootropic”.
• Monoamine systems. In rodents, Semax increased activity of dopaminergic and serotonergic systems [2].

How far these rodent findings translate to people, and at what exposure, is still an open question.

Why Dosing Differs by Variant

Before addressing dose numbers, it is worth understanding why Semax variants are not interchangeable in their dosing.

Standard Semax (heptapeptide: Met-Glu-His-Phe-Pro-Gly-Pro) is the molecule with the longest clinical history — registered as a medicine in Russia and available there at the 0.1% concentration (1 mg/mL) as well as a 1% concentration used in stroke care. According to the Russian label, one drop of the 0.1% formulation contains 50 mcg, so three drops hold 150 mcg.

NA-Semax (N-acetylated Semax) has an acetyl group added to the N-terminus, which is intended to increase resistance to enzymatic degradation in nasal mucosa and plasma. In practical terms, the idea is that a higher fraction of the dose reaches olfactory nerve fibers intact. Users and clinicians who have worked with both forms consistently report that NA-Semax produces more pronounced effects at equivalent microgram doses — meaning the effective dose is lower, not that the molecule is inherently more potent in receptor binding. There is no published human study of NA-Semax.

NA-Semax Amidate adds C-terminal amidation to the already-acetylated backbone, further extending metabolic half-life. It is the most structurally stable variant; claims about stronger BDNF effects per dose are not backed by published human data. Clinical experience suggests starting doses roughly 30–50% lower than NA-Semax until individual tolerance is established.

The practical consequence: someone who transitions from standard Semax 0.1% to NA-Semax Amidate at the same microgram dose will very likely feel over-stimulated. I always advise starting the modified forms at half the mcg equivalent and titrating up over 5–7 days.

Standard Semax 0.1%: Dosing Protocol

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

Starting Titration

For anyone new to Semax or new to intranasal peptides generally, I recommend beginning at the lower end of the dose range regardless of what they may have read about typical clinical doses.

Week 1 (Orientation phase):

• 1–2 drops per nostril once daily = 100–200 mcg total (50 mcg per drop of the 0.1% solution)
• Administer in the morning, 30–60 minutes before cognitive demands begin
• Monitor for stimulant-like effects: increased mental drive, mild restlessness, or headache at the back of the skull (common at higher doses in sensitive individuals)

Week 2–3 (Titration phase):

• If week 1 is well tolerated with desired cognitive effects: remain at this dose
• If effects are subtle: increase to 3 drops per nostril once daily (300 mcg total) or add a second administration in the early afternoon
• Common community upper range: 3 drops per nostril twice daily = 600 mcg/day; community protocols for periods of heavy mental demand use 600-900 mcg/day split into 2-3 doses (Practice protocol, see the table above). The label caps a single application at 2-3 drops per nostril, with further drops after 10-15 minutes.

Upper bound: Russian stroke studies used the 1% formulation at much higher daily doses in inpatient settings (for example, 6,000 mcg/day in two 10-day courses in a 2018 rehabilitation study [3]). For outpatient cognitive enhancement, I rarely advise exceeding 600 mcg/day. Higher doses do not appear to substantially improve cognitive outcomes in otherwise-healthy individuals and increase the probability of transient headache and sleep disruption.

Maintenance Dosing by Indication

The effective dose varies meaningfully by why someone is using Semax:

Cognitive enhancement, focus, executive function: 200–400 mcg/day, once or twice daily, for 14–21 day cycles.

Post-viral brain fog (post-COVID, post-Lyme): 300–600 mcg/day in two divided doses for 21-day cycles. These patients may need longer or repeated courses; the pattern most commonly used is 2–3 cycles spaced 3–4 weeks apart. Brain fog has treatable causes (sleep apnoea, thyroid disease, depression, anaemia, medication effects), so a work-up should come first.

Neuroprotection, age-related cognitive decline: 200–300 mcg/day, once daily in the morning, with longer cycles (21 days) and structured 3-month repetition (e.g., 3 weeks on, 3 weeks off, 3 cycles per quarter).

Acute neurological support (adjunct to stroke or TBI rehabilitation): This should only occur under direct physician oversight. The Russian stroke protocols used the 1% formulation at substantially higher doses in inpatient settings [3]; this article does not constitute a protocol for acute neurological emergencies.

NA-Semax and NA-Semax Amidate: Adjusted Dosing

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

Because these variants circulate primarily from research-grade suppliers rather than pharmaceutical manufacturers, concentration verification is a critical first step. Unlike the standardized Russian 0.1% pharmaceutical, research supplier concentrations vary widely: common formulations include 200 mcg/mL, 500 mcg/mL, and 1 mg/mL. Always confirm concentration with the supplier before calculating a drop-based dose. The doses below come from practitioner experience, not from human trials, because none have been published for these forms.

NA-Semax Dosing Framework

Starting dose: 50–100 mcg/day, once in the morning.

Titration: Increase by 50 mcg every 3–5 days if effects are insufficient. Most people find the effective range at 100–200 mcg/day for cognitive enhancement.

Upper limit: 300 mcg/day is a practical ceiling for most outpatient use. Anecdotal reports suggest diminishing returns beyond this point, with increased incidence of irritability and sleep disruption.

NA-Semax Amidate Dosing Framework

Starting dose: 50 mcg/day, once in the morning.

Titration: More conservative than NA-Semax due to greater metabolic stability. Increase by 25–50 mcg per step every 5–7 days.

Community range: 200–400 mcg per dose, once or twice daily, in cycles of 10–14 days on and 14 days off (Anecdotal: Peptide Protocol Wiki). No human study has tested any dose of this form.

Key caution: The amidate form’s extended half-life means dosing in the afternoon can significantly disrupt sleep. Morning-only administration is strongly preferred.

Nasal Administration Technique

The intranasal route for Semax is thought to exploit olfactory receptor neurons in the upper nasal cavity — the area served by cranial nerve I — to carry the peptide toward the brain, bypassing much of the blood-brain barrier. The technique used determines how much peptide actually reaches this olfactory epithelium versus the lower nasal passages, where systemic absorption is less efficient.

Step-by-Step Protocol

1. Clear the nasal passages. Blow gently or use saline rinse 5–10 minutes before administration. Congestion from allergies or infection substantially reduces olfactory uptake and may necessitate dose deferral.

2. Tilt the head slightly forward (30–45 degrees downward). This is counterintuitive — many people tilt back — but the olfactory epithelium is at the top of the nasal cavity, and forward tilt directs drops upward along the septum toward the olfactory cleft when sniffed gently.

3. Administer drops to one nostril at a time. With the head tilted and the dropper or spray nozzle positioned just inside the nostril, apply drops while inhaling slowly and gently through the nose. Forceful inhalation pulls the liquid to the back of the throat rather than the upper cavity.

4. Sniff gently after each set of drops — not sharply. A single slow sniff is enough to distribute the solution toward the olfactory region.

5. Remain with head forward for 1–2 minutes before switching nostrils. This allows the liquid to rest in contact with the olfactory mucosa rather than draining immediately.

6. Alternate nostrils first. Some practitioners recommend alternating which nostril receives the first dose each morning to distribute mucosal exposure evenly over time.

7. Do not eat or drink immediately before or after (15 minutes minimum). Food can stimulate drainage reflexes that clear the nasal cavity.

Spray vs. Dropper

The Russian pharmaceutical Semax comes as nasal drops in a bottle with a dropper tip. The label states 50 mcg per drop of the 0.1% solution (500 mcg per drop of the 1% solution, where a drop is 50 microlitres), so 2–3 drops per nostril deliver 100–150 mcg per nostril of the 0.1% product. Research-grade Semax often arrives in a sterile vial with a dropper or separate nasal spray bottle.

If using another dropper: a standard ophthalmic dropper delivers approximately 35–50 microlitres per drop at normal room temperature. For a 0.1% solution (1 mg/mL = 1,000 mcg/mL), this means:

• 1 drop ≈ 35–50 mcg
• 3 drops ≈ 105–150 mcg
• 6 drops total (3 per nostril) ≈ 210–300 mcg

These are approximations. Dropper calibration varies; verify your supplier’s stated drop volume if precision matters. Spray bottles deliver a set volume per actuation that differs between products, so check the stated volume per spray before converting to micrograms.

Cycling Protocols and Rest Periods

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

Standard Cycling

The 14–21 day on / 14–21 day off framework used for Selank and other neuropeptides applies equally to Semax. The rationale is partly pharmacological (avoiding receptor downregulation) and partly practical (aligning with the course durations used in Russian clinical studies, such as the 10-day courses in [3]).

Conservative cycle: 14 days on, 14 days off. Appropriate for first-time users and those using Semax primarily as a cognitive productivity tool.

Extended cycle: 21 days on, 21 days off. Used more often in people with post-infectious brain fog or documented cognitive decline where sustained neuroplastic signaling is the goal.

Acute course: 7–10 days on at moderate-to-high dose before a planned cognitive demand (exam period, intensive work project). Not recommended as a long-term pattern but well tolerated as an occasional approach.

Stacking with Other Peptides

Semax combines with several other peptides that are commonly used in cognitive and neuromodulation protocols:

Semax + Selank: This pairing is the most common in Russian clinical practice and among experienced integrative practitioners. Semax provides the dopaminergic drive and BDNF upregulation; Selank contributes anxiolytic and serotonergic modulation. The combination is often described as providing focused calm rather than either stimulation or sedation alone. Use standard doses of each; no dose reduction is needed when stacking these two.

Semax + BPC-157: Used where the cognitive decline is thought to be partly attributable to gut-brain axis dysfunction, chronic inflammation, or tissue repair demands. BPC-157 is administered separately (orally or subcutaneously) and there is no known pharmacokinetic interaction.

Semax + Dihexa: Both upregulate BDNF and HGF/Met signaling respectively. This is a higher-potency cognitive stack generally reserved for significant cognitive impairment, not general enhancement. Doses of each should be at the lower end of the respective therapeutic range when combined. Dihexa has no human safety data and raises a c-Met cancer-risk question; read Dihexa Safety before considering it.

Signs the Dose Needs Adjustment

Dose Is Too High

• Persistent headache localized to the occiput or temples (most common dose-limiting side effect)
• Sleep onset difficulty or early awakening, particularly when afternoon dosing is used
• Irritability or emotional lability out of proportion to baseline
• Pounding or pressured sensation in the head during administration

Action: Reduce by one step (50–100 mcg depending on variant) and assess for 5–7 days before reconsidering upward titration.

Dose Is Insufficient

• No perceptible shift in cognitive clarity or drive after 5–7 days at current dose
• Effects that were present in cycle one are absent in subsequent cycles (possible tolerance — consider extending washout period)

Action: Increase by one step, or extend the washout period between cycles before initiating the next course.

When to Stop

Semax has no documented physical dependence or withdrawal syndrome. Stopping at any point is safe. I advise stopping if you develop significant nasal mucosal irritation, persistent headache unresponsive to dose reduction, or any signs of nasal infection requiring medical treatment.

What the Evidence Shows

Preclinical

The rat and mouse literature is consistent in direction: Semax affects neurotrophin expression and monoamine turnover [1][2]. These are mechanism studies, not efficacy studies.

Human

What does not exist yet: a randomised, blinded trial of Semax for cognitive enhancement in healthy people, for post-viral brain fog, or for age-related cognitive decline, published in a journal outside Russia. There is also no human study of NA-Semax or NA-Semax Amidate. The outpatient doses above come from practice, not from such trials.

Known and Theoretical Risks

• Limited safety data. The Russian studies report few adverse effects, but they were small and not designed to detect uncommon harms. Long-term safety of repeated courses is unknown.
• Product quality. Research-grade peptides sold online are not made or tested to pharmaceutical standards. When researchers test-bought semaglutide from illegal online sellers, purity was far below the label and endotoxin was found in every sample [5]. There is no reason to assume nasal peptide products are cleaner.
• Nasal administration of non-sterile solutions can irritate the mucosa or introduce infection.
• Immunogenicity and impurities. The FDA lists Semax among peptides whose compounded forms “may pose risk for immunogenicity” because of aggregation and peptide-related impurities, and states it has “no, or limited, safety-related information” for the proposed routes [6].
• Stimulant-type effects. Headache, sleep disturbance and irritability are the effects most often described anecdotally. They are not well quantified.
• Masking a real problem. Brain fog, memory complaints and poor concentration have treatable causes. Self-treating with a nootropic can delay the diagnosis.

Regulatory Status

• EU and Germany. Semax is not authorised by the EMA or by Germany’s BfArM. However it is labelled, a “research use only” vial is not an approved medicine and has not been tested for human use.
• United States. Semax is not FDA-approved. FDA’s page on bulk substances that may present significant safety risks (content current as of 22 April 2026) lists Semax among substances previously in category 2 whose compounding nominations were withdrawn; FDA’s safety statement remains on that page [6]. As of FDA’s May 2026 list, Semax is not on the 503A bulks list and not in category 1 (“under evaluation”).
• Russia. Registered as a medicine and used in neurology.
• Sport. Not named on the WADA 2026 Prohibited List. Section S0 covers any pharmacological substance without current human-use approval by a governmental health authority, so athletes should not assume it is permitted.

When to Talk to a Physician

• If you are considering Semax for brain fog, memory problems or recovery after a stroke or infection, start with a work-up of the problem itself. Bring a list of symptoms, their timeline, current medicines and any prior test results.
• If you already use a grey-market product, tell your physician. It matters for interpreting symptoms and lab results.
• Stop and seek care for severe headache, nosebleeds, signs of infection, chest pain, or any neurological change.
• Registered clinical trials are another route: search ClinicalTrials.gov or the EU Clinical Trials Register.

Back to Semax overview | All Peptide Articles

Related Articles

• Semax: The Nootropic Peptide That Amplifies BDNF and Protects the Brain — full mechanism, clinical evidence, and variant comparison
• Selank Dosage: Nasal Spray Protocol and Cycling — companion dosage guide for the anxiolytic neuropeptide most commonly stacked with Semax
• Selank vs. Semax: Which Nootropic Peptide Fits Your Cognitive Goals? — head-to-head comparison to guide choice between the two
• Nootropic Peptides: A Clinician’s Guide — broader survey of cognitive peptides and where Semax fits in the landscape
• Peptide Therapy for Women: Dosage Adjustments and Hormonal Context — how estrogen status and hormonal fluctuations affect peptide dosing